 |
|
||
|
 |
||||||||||
 |
||||||||||
 |
||||||||||
|
||||||||||
 |
||||||||||
|
||||||||||
 |
||||||||||
|
||||||||||
|
 iPad compatible version can be now be downloaded |
 |
 |
| SCImago Journal & Country Rank |
 |
 |
| The African Journal Archive is a retrospective digitisation project of full-text journal articles published in Africa. Older CVJA articles can be viewed here. |
 |
|||
 |
|||
|
|
|||
| WELCOME TO THE CARDIOVASCULAR JOURNAL OF AFRICA | |||
 |
The Cardiovascular Journal of Africa (CVJA) is
an international peer-review journal that keeps cardiologists up
to date with advances in the diagnosis and treatment of cardiovascular
disease. Topics covered include coronary disease, electrophysiology, valve disease, imaging techniques, congenital heart disease (fetal, paediatric & adult), heart failure, surgery, & basic science. CVJA is the official journal of the PASCAR and has been published since 1990. |
||
| CVJA Readership
Increased by 33% - Pubmed Statistics The most recent report on the link-out facility to full text articles published in the CVJA shows a 30% increase in readership in January this year. Read More » Latest News Dabigatran approved in UK NHS for stroke prevention in atrial fibrillation Importance of assessment of renal function in dabigatran treatment re-affirmed. The NICE guideline committee has approved the use of dabigatran etexilate for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF), based on the RE-LY studies and additional cost-effectiveness data. It has included this recommendation in its final appraisal determination. Read More » Dramatic reductions in plaque volumes on maximum statin therapy: Largest IVUS trial shows equal plaque regression with atorvastatin and rosuvastatin The SATURN trial, which evaluated the extent of plaque regression in patients with symptomatic coronary artery disease (CAD) over a two-year period using maximum doses of atorvastatin and rosuvastatin, showed no difference between these two statins with regard to the primary endpoint of percentage reduction of atheroma volume. Read More » Raft of Rivaroxaban: good news from the USA, implications for SA clinical practice Rivaroxaban has been approved by the US Food and Drug Administration (FDA) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation. From the American Heart Association (AHA) 2011 congress earlier this week, the results of the ATLAS ACS 2-TIMI 51 trial have shown rivaroxiban improves cardiovascular outcomes and reduces cardiovascular and all-cause mortality in acute coronary syndromes (ACS). Read more » |
|||
|
|||
|
Latest Cardiovascular Journal of Africa Vol 22, Issue 6
|
|||
| News for Authors: | |||
|
The CVJA Online First Advanced Publication latest articles:
|
|||
© 2011 All Rights Reserved
Disclaimer